Irm LLC

Novartis Ag

Jiqing Jiang

Yongqin Wan

Shifeng Pan

Dai Cheng

Wenqi Gao

Dong Han

Nathanael Schiander Gray

Yi Liu

Bao Vinh Nguyen

Hank Michael James Petrassi

Ruo W Steensma

James Paul Lajiness

Ha-Soon Choi

Yun Feng Xie

Donald Karanewsky

Qiang Ding

Guobao Zhang

Greg Chopiuk

Yang Yang

Qiong Zhang

Xing Wang

Yongping Xie

Keiichi Masuya

Badry Bursulaya

Ichiro Umemura

Taebo Sim

Carlos Garcia-Echeverria

Xia Wang

Shuli You

Takanori Kanazawa

Zhicheng Wang

Xu Wu

Naoko Matsuura

Osamu Ohmori

Takahiro Miyake

Qihui Jin

Eiji Kawahara

Donald S Karanewsky

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;

Compounds and compositions for inducing chondrogenesis

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes. 

The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).

Hedgehog pathway modulators

The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I). 

Compounds and compositions as hedgehog pathway inhibitors

The invention provides a novel class of compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb). 

Compounds and compositions as ITPKb inhibitors

The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.

Compounds and compositions as hedgehog pathway modulators

The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I. 

Compounds and compositions as hedgehog signaling pathway modulators

Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, lck, SAPK2&#x3b1;, p38, TGF&#x3b2;, KDR, c-Kit, b-RAF, c-RAF, FLT1 and FLT4 kinases.

Compounds and compositions as protein kinase inhibitors

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGF&#x3b2;, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2&#x3b2; kinases.

Growing community of inventors

San Diego, CA, United States of America

Jiqing Jiang